Cargando…

Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling

Left ventricular hypertrophy (LVH) is an important characteristic of hypertensive heart disease. Renin-angiotensin system (RAS) blockers have been shown to be effective drugs for the reversal of LVH. Clinical and experimental studies have shown that Zi Shen Huo Luo Formula (ZSHLF) can improve the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Xiaotong, Zhao, Yue, Wang, Shijun, Wang, Yuan, Chen, Qian, Zhao, Haijun, Wang, Hua, Tian, Sheng, Yu, Huayun, Wu, Zhichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147343/
https://www.ncbi.nlm.nih.gov/pubmed/32317965
http://dx.doi.org/10.3389/fphar.2020.00383
_version_ 1783520400603348992
author Song, Xiaotong
Zhao, Yue
Wang, Shijun
Wang, Yuan
Chen, Qian
Zhao, Haijun
Wang, Hua
Tian, Sheng
Yu, Huayun
Wu, Zhichun
author_facet Song, Xiaotong
Zhao, Yue
Wang, Shijun
Wang, Yuan
Chen, Qian
Zhao, Haijun
Wang, Hua
Tian, Sheng
Yu, Huayun
Wu, Zhichun
author_sort Song, Xiaotong
collection PubMed
description Left ventricular hypertrophy (LVH) is an important characteristic of hypertensive heart disease. Renin-angiotensin system (RAS) blockers have been shown to be effective drugs for the reversal of LVH. Clinical and experimental studies have shown that Zi Shen Huo Luo Formula (ZSHLF) can improve the efficacy of perindopril in the treatment of hypertensive LVH, but its mechanism is unclear. This study aimed to investigate the possible mechanism to improve the efficacy of perindopril. First, we identified 23 compounds in ZSHLF by ultra performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) analysis, among which ferulic acid, caffeic acid, vanillic acid, berberine, rutin, quercetin, kaempferol, stachydrine, and tiliroside have been reported to reduce blood pressure and exhibit cardioprotective effects. Second, we treated spontaneously hypertensive rats (SHRs) with perindopril and ZSHLF for 12 continuous weeks and found that chronic use of perindopril could increase the aldosterone (ALD) levels and cause aldosterone breakthrough (ABT). ZSHLF combined with perindopril reduced the ALD levels, interfered with ABT, decreased blood pressure, improved left ventricular diastolic dysfunction, and decreased the collagen volume fraction; these effects were superior to those of perindopril alone. In vitro experiments, ALD-induced cardiomyocytes (H9c2 cells) and cardiac fibroblasts were treated with ZSHLF-containing serum, which suppressed ALD-induced cardiomyocyte hypertrophy and cardiac fibroblast proliferation, increased mineralocorticoid receptor (MR) and Cav-1 colocalization and decreased phosphorylated epidermal growth factor receptor (pEGFR) and phosphorylated extracellular signal-regulated kinase (pERK) protein expression the cells. In conclusion, ZSHLF can interfere with ABT and affect the pathological role of ALD by affecting MR and Cav-1 interactions and EGFR/ERK signaling pathway. These effects represent a possible mechanism by which ZSHLF improves the efficacy of angiotensin-converting enzyme inhibitors (ACEIs) in hypertensive LVH treatment. However, the major bioactive components or metabolites responsible for the effects and the implications of these findings in patients need further verification.
format Online
Article
Text
id pubmed-7147343
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-71473432020-04-21 Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling Song, Xiaotong Zhao, Yue Wang, Shijun Wang, Yuan Chen, Qian Zhao, Haijun Wang, Hua Tian, Sheng Yu, Huayun Wu, Zhichun Front Pharmacol Pharmacology Left ventricular hypertrophy (LVH) is an important characteristic of hypertensive heart disease. Renin-angiotensin system (RAS) blockers have been shown to be effective drugs for the reversal of LVH. Clinical and experimental studies have shown that Zi Shen Huo Luo Formula (ZSHLF) can improve the efficacy of perindopril in the treatment of hypertensive LVH, but its mechanism is unclear. This study aimed to investigate the possible mechanism to improve the efficacy of perindopril. First, we identified 23 compounds in ZSHLF by ultra performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) analysis, among which ferulic acid, caffeic acid, vanillic acid, berberine, rutin, quercetin, kaempferol, stachydrine, and tiliroside have been reported to reduce blood pressure and exhibit cardioprotective effects. Second, we treated spontaneously hypertensive rats (SHRs) with perindopril and ZSHLF for 12 continuous weeks and found that chronic use of perindopril could increase the aldosterone (ALD) levels and cause aldosterone breakthrough (ABT). ZSHLF combined with perindopril reduced the ALD levels, interfered with ABT, decreased blood pressure, improved left ventricular diastolic dysfunction, and decreased the collagen volume fraction; these effects were superior to those of perindopril alone. In vitro experiments, ALD-induced cardiomyocytes (H9c2 cells) and cardiac fibroblasts were treated with ZSHLF-containing serum, which suppressed ALD-induced cardiomyocyte hypertrophy and cardiac fibroblast proliferation, increased mineralocorticoid receptor (MR) and Cav-1 colocalization and decreased phosphorylated epidermal growth factor receptor (pEGFR) and phosphorylated extracellular signal-regulated kinase (pERK) protein expression the cells. In conclusion, ZSHLF can interfere with ABT and affect the pathological role of ALD by affecting MR and Cav-1 interactions and EGFR/ERK signaling pathway. These effects represent a possible mechanism by which ZSHLF improves the efficacy of angiotensin-converting enzyme inhibitors (ACEIs) in hypertensive LVH treatment. However, the major bioactive components or metabolites responsible for the effects and the implications of these findings in patients need further verification. Frontiers Media S.A. 2020-04-03 /pmc/articles/PMC7147343/ /pubmed/32317965 http://dx.doi.org/10.3389/fphar.2020.00383 Text en Copyright © 2020 Song, Zhao, Wang, Wang, Chen, Zhao, Wang, Tian, Yu and Wu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Song, Xiaotong
Zhao, Yue
Wang, Shijun
Wang, Yuan
Chen, Qian
Zhao, Haijun
Wang, Hua
Tian, Sheng
Yu, Huayun
Wu, Zhichun
Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling
title Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling
title_full Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling
title_fullStr Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling
title_full_unstemmed Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling
title_short Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling
title_sort zi shen huo luo formula enhances the therapeutic effects of angiotensin-converting enzyme inhibitors on hypertensive left ventricular hypertrophy by interfering with aldosterone breakthrough and affecting caveolin-1/mineralocorticoid receptor colocalization and downstream extracellular signal-regulated kinase signaling
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147343/
https://www.ncbi.nlm.nih.gov/pubmed/32317965
http://dx.doi.org/10.3389/fphar.2020.00383
work_keys_str_mv AT songxiaotong zishenhuoluoformulaenhancesthetherapeuticeffectsofangiotensinconvertingenzymeinhibitorsonhypertensiveleftventricularhypertrophybyinterferingwithaldosteronebreakthroughandaffectingcaveolin1mineralocorticoidreceptorcolocalizationanddownstreamextracellularsi
AT zhaoyue zishenhuoluoformulaenhancesthetherapeuticeffectsofangiotensinconvertingenzymeinhibitorsonhypertensiveleftventricularhypertrophybyinterferingwithaldosteronebreakthroughandaffectingcaveolin1mineralocorticoidreceptorcolocalizationanddownstreamextracellularsi
AT wangshijun zishenhuoluoformulaenhancesthetherapeuticeffectsofangiotensinconvertingenzymeinhibitorsonhypertensiveleftventricularhypertrophybyinterferingwithaldosteronebreakthroughandaffectingcaveolin1mineralocorticoidreceptorcolocalizationanddownstreamextracellularsi
AT wangyuan zishenhuoluoformulaenhancesthetherapeuticeffectsofangiotensinconvertingenzymeinhibitorsonhypertensiveleftventricularhypertrophybyinterferingwithaldosteronebreakthroughandaffectingcaveolin1mineralocorticoidreceptorcolocalizationanddownstreamextracellularsi
AT chenqian zishenhuoluoformulaenhancesthetherapeuticeffectsofangiotensinconvertingenzymeinhibitorsonhypertensiveleftventricularhypertrophybyinterferingwithaldosteronebreakthroughandaffectingcaveolin1mineralocorticoidreceptorcolocalizationanddownstreamextracellularsi
AT zhaohaijun zishenhuoluoformulaenhancesthetherapeuticeffectsofangiotensinconvertingenzymeinhibitorsonhypertensiveleftventricularhypertrophybyinterferingwithaldosteronebreakthroughandaffectingcaveolin1mineralocorticoidreceptorcolocalizationanddownstreamextracellularsi
AT wanghua zishenhuoluoformulaenhancesthetherapeuticeffectsofangiotensinconvertingenzymeinhibitorsonhypertensiveleftventricularhypertrophybyinterferingwithaldosteronebreakthroughandaffectingcaveolin1mineralocorticoidreceptorcolocalizationanddownstreamextracellularsi
AT tiansheng zishenhuoluoformulaenhancesthetherapeuticeffectsofangiotensinconvertingenzymeinhibitorsonhypertensiveleftventricularhypertrophybyinterferingwithaldosteronebreakthroughandaffectingcaveolin1mineralocorticoidreceptorcolocalizationanddownstreamextracellularsi
AT yuhuayun zishenhuoluoformulaenhancesthetherapeuticeffectsofangiotensinconvertingenzymeinhibitorsonhypertensiveleftventricularhypertrophybyinterferingwithaldosteronebreakthroughandaffectingcaveolin1mineralocorticoidreceptorcolocalizationanddownstreamextracellularsi
AT wuzhichun zishenhuoluoformulaenhancesthetherapeuticeffectsofangiotensinconvertingenzymeinhibitorsonhypertensiveleftventricularhypertrophybyinterferingwithaldosteronebreakthroughandaffectingcaveolin1mineralocorticoidreceptorcolocalizationanddownstreamextracellularsi